Published in Biochemistry on December 12, 1989
Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. Proc Natl Acad Sci U S A (1995) 1.83
Human serum amyloid P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure. Proc Natl Acad Sci U S A (1994) 1.35
The connection between C-reactive protein and atherosclerosis. Ann Med (2008) 1.29
Pentraxins: structure, function, and role in inflammation. ISRN Inflamm (2013) 1.23
Pattern recognition by pentraxins. Adv Exp Med Biol (2009) 1.19
Structural and functional comparison of native pentameric, denatured monomeric and biotinylated C-reactive protein. Immunology (2006) 1.16
Complement factor H binds at two independent sites to C-reactive protein in acute phase concentrations. J Biol Chem (2009) 1.15
Complement factor H binds to denatured rather than to native pentameric C-reactive protein. J Biol Chem (2008) 1.15
The pentraxins, C-reactive protein and serum amyloid P component, are cleared and catabolized by hepatocytes in vivo. J Clin Invest (1994) 1.11
Binding of the monomeric form of C-reactive protein to enzymatically-modified low-density lipoprotein: effects of phosphoethanolamine. Clin Chim Acta (2009) 1.05
Interaction of calcium-bound C-reactive protein with fibronectin is controlled by pH: in vivo implications. J Biol Chem (2004) 1.00
Identification of acidic pH-dependent ligands of pentameric C-reactive protein. J Biol Chem (2010) 0.96
A protease-sensitive site in the proposed Ca(2+)-binding region of human serum amyloid P component and other pentraxins. Protein Sci (1992) 0.90
C-reactive protein exists in an NaCl concentration-dependent pentamer-decamer equilibrium in physiological buffer. J Biol Chem (2009) 0.89
C-reactive protein induced rearrangement of phosphatidylcholine on nanoparticle mimics of lipoprotein particles. J Phys Chem B (2010) 0.89
Reactivity of anti-human C-reactive protein (CRP) and serum amyloid P component (SAP) monoclonal antibodies with limulin and pentraxins of other species. Immunology (1992) 0.79
Solubilization and purification of recombinant modified C-reactive protein from inclusion bodies using reversible anhydride modification. Biophys Rep (2015) 0.78
Predicting the disruption by UO2(2+) of a protein-ligand interaction. Protein Sci (2010) 0.76
An Intrinsically Disordered Motif Mediates Diverse Actions of Monomeric C-reactive Protein. J Biol Chem (2016) 0.76
Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med (2001) 18.25
The structure of an antigenic determinant in a protein. Cell (1984) 10.85
General method for the rapid solid-phase synthesis of large numbers of peptides: specificity of antigen-antibody interaction at the level of individual amino acids. Proc Natl Acad Sci U S A (1985) 8.77
Chemotactic response to human C3a and C5a anaphylatoxins. I. Evaluation of C3a and C5a leukotaxis in vitro and under stimulated in vivo conditions. J Immunol (1978) 6.04
Object-related activity revealed by functional magnetic resonance imaging in human occipital cortex. Proc Natl Acad Sci U S A (1995) 5.98
Protection against foot-and-mouth disease by immunization with a chemically synthesized peptide predicted from the viral nucleotide sequence. Nature (1982) 5.50
Roles of PLC-beta2 and -beta3 and PI3Kgamma in chemoattractant-mediated signal transduction. Science (2000) 4.61
Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum (2001) 4.60
Generation of protein-reactive antibodies by short peptides is an event of high frequency: implications for the structural basis of immune recognition. Proc Natl Acad Sci U S A (1983) 4.56
Interactions of the complement system with endotoxic lipopolysaccharide: consumption of each of the six terminal complement components. J Exp Med (1968) 4.19
The reactivity of anti-peptide antibodies is a function of the atomic mobility of sites in a protein. Nature (1984) 4.05
Immune pathways and defence mechanisms in honey bees Apis mellifera. Insect Mol Biol (2006) 3.98
High-level semi-synthetic production of the potent antimalarial artemisinin. Nature (2013) 3.80
Inhibition of tyrosine phosphorylation prevents T-cell receptor-mediated signal transduction. Proc Natl Acad Sci U S A (1990) 3.69
Anaphylatoxins: C3a and C5a. Adv Immunol (1978) 3.44
Interactions of the complement system with endotoxic lipopolysaccharide. Generation of a factor chemotactic for polymorphonuclear leukocytes. J Exp Med (1968) 3.33
Characterization of C-reactive protein and the complement subcomponent C1t as homologous proteins displaying cyclic pentameric symmetry (pentraxins). Proc Natl Acad Sci U S A (1977) 3.13
Demonstration of specific C5a receptor on intact human polymorphonuclear leukocytes. Proc Natl Acad Sci U S A (1978) 3.08
Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle. Nat Genet (1996) 3.02
A conformational transition at the N terminus of the prion protein features in formation of the scrapie isoform. J Mol Biol (1997) 2.95
Partial characterization of human C5a anaphylatoxin. I. Chemical description of the carbohydrate and polypeptide prtions of human C5a. J Immunol (1976) 2.90
Interactions of the complement system with the surface and endotoxic lipopolysaccharide of Veillonella alcalescens. J Exp Med (1967) 2.87
Airtraq laryngoscope versus conventional Macintosh laryngoscope: a systematic review and meta-analysis. Anaesthesia (2011) 2.83
Reaction of a cobra venom factor with guinea pig complement and generation of an activity chemotactic for polymorphonuclear leukocytes. Proc Soc Exp Biol Med (1969) 2.76
Determination of the tryptophan content of proteins by ion exchange chromatography of alkaline hydrolysates. J Biol Chem (1972) 2.72
Complement activity and inflammatory neutrophil exudation in man. Studies in patients with glomerulonephritis, essential hypocomplementemia and agammaglobulinemia. Int Arch Allergy Appl Immunol (1967) 2.64
Mapping the prion protein using recombinant antibodies. J Virol (1998) 2.64
Accurate Monte Carlo simulations for nozzle design, commissioning and quality assurance for a proton radiation therapy facility. Med Phys (2004) 2.64
Complement activation during cardiopulmonary bypass: evidence for generation of C3a and C5a anaphylatoxins. N Engl J Med (1981) 2.63
Release of histamine from rat mast cells by the complement peptides C3a and C5a. Immunology (1975) 2.62
Human T-cell recognition of the circumsporozoite protein of Plasmodium falciparum: immunodominant T-cell domains map to the polymorphic regions of the molecule. Proc Natl Acad Sci U S A (1988) 2.60
The alternative pathway C3/C5 convertase: chemical basis of factor B activation. J Immunol (1979) 2.58
Cytotoxic T cells specific for the circumsporozoite protein of Plasmodium falciparum. Nature (1988) 2.56
A neutrophil chemotatic factor derived from C'5 upon interaction of guinea pig serum with endotoxin. J Immunol (1969) 2.54
Chemical basis of antigenic variation in foot-and-mouth disease virus. Nature (1984) 2.52
T cell activation induces rapid tyrosine phosphorylation of a limited number of cellular substrates. J Biol Chem (1989) 2.50
Interactions of C-reactive protein with the complement system. I. Protamine-induced consumption of complement in acute phase sera. J Exp Med (1974) 2.47
First analysis of cancer incidence and occupational radiation exposure based on the National Dose Registry of Canada. Am J Epidemiol (2001) 2.44
The carriage of Escherichia coli resistant to antimicrobial agents by healthy children in Boston, in Caracas, Venezuela, and in Qin Pu, China. N Engl J Med (1990) 2.40
Neoantigen of the polymerized ninth component of complement. Characterization of a monoclonal antibody and immunohistochemical localization in renal disease. J Clin Invest (1983) 2.39
The complement profile in acute glomerulonephritis systemic lupus erythematosus and hypocomplementemic chronic glomerulonephritis. Contrasts and experimental correlations. Int Arch Allergy Appl Immunol (1968) 2.38
Folding of immunogenic peptide fragments of proteins in water solution. II. The nascent helix. J Mol Biol (1988) 2.33
Primary structural analysis of the polypeptide portion of human C5a anaphylatoxin. Polypeptide sequence determination and assignment of the oligosaccharide attachment site in C5a. J Biol Chem (1978) 2.32
Hormone-stimulated polyphosphoinositide breakdown in rat liver plasma membranes. Roles of guanine nucleotides and calcium. J Biol Chem (1986) 2.32
Folding of immunogenic peptide fragments of proteins in water solution. I. Sequence requirements for the formation of a reverse turn. J Mol Biol (1988) 2.30
DMC1 functions in a Saccharomyces cerevisiae meiotic pathway that is largely independent of the RAD51 pathway. Genetics (1997) 2.26
A two-year randomized clinical trial of chlorhexidine varnish on dental caries in Chinese preschool children. J Dent Res (2006) 2.22
Three-dimensional visualization of tegument/capsid interactions in the intact human cytomegalovirus. Virology (1999) 2.20
C-reactive protein and the acute phase response. Adv Intern Med (1982) 2.20
Significance of complement to the mechanism of action of endotoxin. Curr Top Microbiol Immunol (1969) 2.18
C-reactive protein is protective against Streptococcus pneumoniae infection in mice. J Exp Med (1981) 2.17
Effects on C-reactive protein on the lymphoid system. I. Binding to thymus-dependent lymphocytes and alteration of their functions. J Exp Med (1975) 2.17
Case-control study of the D2 dopamine receptor gene and smoking status in lung cancer patients. J Natl Cancer Inst (1998) 2.16
The murine winged helix transcription factors, Foxc1 and Foxc2, are both required for cardiovascular development and somitogenesis. Genes Dev (2001) 2.15
Effects of the acute phase response on the concentration and density distribution of plasma lipids and apolipoproteins. J Lipid Res (1989) 2.10
Cytotoxic T cells recognize a peptide from the circumsporozoite protein on malaria-infected hepatocytes. J Exp Med (1990) 2.09
Human anaphylatoxin (C3a) from the third component of complement. Primary structure. J Biol Chem (1975) 2.08
Structure and function of the anaphylatoxins. Springer Semin Immunopathol (1984) 2.07
A novel gene causing a mendelian audiogenic mouse epilepsy. Neuron (2001) 2.05
Interaction of C-reactive protein with lymphocytes and monocytes: complement-dependent adherence and phagocytosis. J Immunol (1976) 2.02
Nucleotide sequence of cDNA and derived amino acid sequence of human complement component C9. Proc Natl Acad Sci U S A (1984) 2.01
Identifying and recruiting healthy control subjects from a managed care organization: a methodology for molecular epidemiological case-control studies of cancer. Cancer Epidemiol Biomarkers Prev (1997) 1.98
Absence of the sixth component of complement in a patient with repeated episodes of meningococcal meningitis. J Pediatr (1976) 1.98
Estimating cancer risk in relation to tritium exposure from routine operation of a nuclear-generating station in Pickering, Ontario. Chronic Dis Inj Can (2013) 1.97
Activation of complement components C3 and C5 by a cysteine proteinase (gingipain-1) from Porphyromonas (Bacteroides) gingivalis. J Biol Chem (1992) 1.96
Radioimmunoassay of human C-reactive protein and levels in normal sera. J Lab Clin Med (1976) 1.95
Chronic glomerulonephritis associated with low serum complement activity (chronic hypocomplementemic glomerulonephritis). Medicine (Baltimore) (1970) 1.94
Identification of an epitope in the major envelope protein of Epstein-Barr virus that mediates viral binding to the B lymphocyte EBV receptor (CR2). Cell (1989) 1.93
Spatially varying optical property reconstruction using a finite element diffusion equation approximation. Med Phys (1995) 1.92
Passive hemolysis by serum and cobra venom factor: a new mechanism inducing membrane damage by complement. Proc Natl Acad Sci U S A (1969) 1.92
Induction of broadly cross-reactive cytotoxic T cells recognizing an HIV-1 envelope determinant. Science (1992) 1.89
Rapid identification of high affinity peptide ligands using positional scanning synthetic peptide combinatorial libraries. Biotechniques (1992) 1.89
Interactions of C-reactive protein with the complement system. II. C-reactive protein-mediated consumption of complement by poly-L-lysine polymers and other polycations. J Exp Med (1975) 1.88
Human beta-endorphin: synthesis and characterization of analogs iodinated and tritiated at tyrosine residues 1 and 27. Int J Pept Protein Res (1980) 1.88
Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. Am J Transplant (2012) 1.88
Interactions of the complement system with native and chemically modified endotoxins. J Bacteriol (1968) 1.87
Decreased properdin activity in acute glomerulonephritis. Int Arch Allergy Appl Immunol (1969) 1.83
Purification and partial characterization of human and porcine C3a anaphylatoxin. J Biol Chem (1975) 1.82
Hemolytic and antimicrobial activities of the twenty-four individual omission analogues of melittin. Biochemistry (1991) 1.81
Benzo[a]pyrene diol epoxide and bleomycin sensitivity and susceptibility to cancer of upper aerodigestive tract. J Natl Cancer Inst (1998) 1.81
Regulation of complement activation by C-reactive protein. Immunopharmacology (1999) 1.78
Requirement and role of C5a in acute lung inflammatory injury in rats. J Clin Invest (1996) 1.77
Isolation of three separate anaphylatoxins from complement-activated human serum. Mol Cell Biochem (1981) 1.70
Broad-spectrum, transmissible beta-lactamases. N Engl J Med (1988) 1.70
Two cortical areas mediate multisensory integration in superior colliculus neurons. J Neurophysiol (2001) 1.68
C-reactive protein and the acute-phase response. J Lab Clin Med (1981) 1.67
Viral escape by selection of cytotoxic T cell-resistant variants in influenza A virus pneumonia. J Exp Med (2000) 1.65
Design of model amphipathic peptides having potent antimicrobial activities. Biochemistry (1992) 1.63
Mapping of functional and antigenic domains of the alpha 4 protein of herpes simplex virus 1. J Virol (1988) 1.63
A T cell clone directed at the circumsporozoite protein which protects mice against both Plasmodium yoelii and Plasmodium berghei. J Immunol (1992) 1.62
Identification of MECL-1 (LMP-10) as the third IFN-gamma-inducible proteasome subunit. J Immunol (1996) 1.62
China at the crossroads: the economics of tobacco and health. Tob Control (2006) 1.62
Downregulation of Wnt2 and beta-catenin by siRNA suppresses malignant glioma cell growth. Cancer Gene Ther (2008) 1.61
Complement and complement-like activity in lower vertebrates and invertebrates. J Exp Med (1970) 1.61
Human cytotoxic T lymphocytes against the Plasmodium falciparum circumsporozoite protein. Proc Natl Acad Sci U S A (1991) 1.61
Polyarginines are potent furin inhibitors. J Biol Chem (2000) 1.60
Frequency-domain fluorescent diffusion tomography: a finite-element-based algorithm and simulations. Appl Opt (1998) 1.60
Binding and in vitro activities of peptides with high affinity for the nociceptin/orphanin FQ receptor, ORL1. J Pharmacol Exp Ther (1997) 1.59
Early local generation of C5a initiates the elicitation of contact sensitivity by leading to early T cell recruitment. J Immunol (2000) 1.57